Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3] Financial Reporting - Lifecore will report its financial results for the first quarter of fiscal year 2025 on October 4, 2024, prior to market open [1] - A webcast will be hosted at 8:30 a.m. Eastern Time to discuss the financial results and recent corporate developments [1][2]